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The human xeroderma pigmentosum (XP) group 
D gene (XPD/ERCC2) is located on 19q13. 
XPD encodes an ATP-dependent 5-3 heli-
case of 760 amino acids, which is a subunit of 
the multiprotein complex, TFIIH. In addi-
tion to helicase activity, XPD is intrinsically   
involved in the maintenance of the TFIIH 
integrity by promoting the interaction between 
the CAK subcomplex (cdk activating kinase, 
containing  cyclin  H,  MAT1,  and  the  kinase 
cdk7) and the core of TFIIH (including the 3-5 
helicase XPB and proteins p62, p52, p44, p34, 
and p8/TTDA). TFIIH was initially defined as 
a basal transcription factor for RNA polymerase 
II (RNA pol II). This complex is also involved 
in transcription mediated by RNA polymerase I 
(Iben et al., 2002), as well as in the nucleo-
tide excision repair (NER) pathway. In NER, 
TFIIH, through the enzymatic activity of XPD 
and XPB, unwinds the DNA around lesions 
generated by UV irradiation or bulky chemical 
adducts. In the transcription of protein coding 
genes, where the preinitiation complex is assem-
bled (including TFIIA, TFIIB, TFIID, TFIIE, 
TFIIF, and RNA pol II), TFIIH opens DNA 
around the proximal promoter through its XPB 
subunit (Holstege et al., 1996) and phosphory-
lates the C-terminal domain of the largest sub-
unit of RNA pol II via its kinase cdk7 (Feaver 
et al., 1991; O’Brien et al., 1994). This phos-
phorylation is a prerequisite for promoter escape 
(Dvir et al., 1997).
Mutations in the XPD gene result in several 
different rare autosomal recessive disorders,   
including xeroderma pigmentosum (XP), tricho-
thiodystrophy  (TTD),  combined  XP  and 
Cockayne syndrome, or combined XP and 
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Mutations in the XPD subunit of the DNA repair/transcription factor TFIIH result in the rare 
recessive genetic disorder xeroderma pigmentosum (XP). Many XP patients are compound 
heterozygotes with a “causative” XPD point mutation R683W and different second mutant 
alleles, considered “null alleles.” However, there is marked clinical heterogeneity (including 
presence or absence of skin cancers or neurological degeneration) in these XPD/R683W 
patients, thus suggesting a contribution of the second allele. Here, we report XP patients 
carrying XPD/R683W and a second XPD allele either XPD/Q452X, /I455del, or /199insPP. 
We performed a systematic study of the effect of these XPD mutations on several enzy-
matic functions of TFIIH and found that each mutation exhibited unique biochemical 
properties. Although all the mutations inhibited the nucleotide excision repair (NER) by 
disturbing the XPD helicase function, each of them disrupted specific molecular steps 
during transcription: XPD/Q452X hindered the transactivation process, XPD/I455del dis-
turbed RNA polymerase II phosphorylation, and XPD/199insPP inhibited kinase activity of 
the cdk7 subunit of TFIIH. The broad range and severity of clinical features in XP patients 
arise from a broad set of deficiencies in NER and transcription that result from the combi-
nation of mutations found on both XPD alleles.
© 2009 Ueda et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Computed tomography scans of the brain showed diffuse atro-
phy of the cerebral cortex and enlargement of the ventricles, but 
no calcification (unpublished data). They died in 2008 at the age 
of 35 and 39, respectively, of progressive cachexia associated 
with neurodegeneration.
To assign the cells from these patients to an XP complemen-
tation group, we measured the DNA repair ability of fibroblasts 
using the host cell reactivation assay (Khan et al., 1998). A plas-
mid (pCMV-luc) encoding the luciferase reporter gene was ex-
posed to 1,000 J/m2 of UVC radiation (254 nm, which generates 
100 photolesions per 5 kb of DNA; van Hoffen et al., 1995), 
and then transfected into AS552 and maternal (AS550) fibro-
blasts (Fig. 2 A). The luciferase activity was strongly reduced in 
AS552 cells when compared with that observed in the maternal 
fibroblasts (Fig. 2 A, left two columns), demonstrating that the 
NER activity is deficient in these cells. Strikingly, an overex-
pression of the WT XPD subunit greatly increased the luciferase 
activity in AS552 fibroblasts (Fig. 2 A, right two columns), dem-
onstrating that the NER defect in these patients is associated 
with  a  XPD  deficiency.  Similar  results  were  obtained  from 
AS553 cells (not depicted).
Many XP patients with mutations in the XPD gene have a 
R683W point mutation, which corresponds to a C-to-T sub-
stitution at the first base of exon 22 in the XPD gene (Taylor   
et al., 1997; Kobayashi et al., 2002; Boyle et al., 2008; Emmert 
et al., 2009). This mutation abolishes the restriction site for the 
endonuclease MspA1l (Fig. 2 B). Genomic DNA was extracted 
from AS550, AS551, AS552, and AS553 cell lines, and control 
normal fibroblasts (FB789). Restriction fragment length poly-
morphisms were assessed from a PCR product (329 bp) con-
taining the putative R683W substitution, which was digested 
by MspA1l. Restriction analysis of the AS551-DNA (the 
father) resulted in a fragment of 256 bp that is identical to that 
obtained from WT FB789 fibroblasts (Fig. 2 C, lanes 4 and 10). 
In contrast, the two hydrolyzed fragments that were obtained 
from the genomic DNA of the mother AS550 (lane 2) were 
also found within the AS552- and the AS553-DNA (lanes 
6 and 8), suggesting that the AS552/553 patients are heterozy-
gous for the XPD point mutation R683W. We then searched 
for the mutation in the second XPD allele. mRNA were iso-
lated from AS552 fibroblasts and reverse transcribed. After se-
quencing, we found on the second XPD allele, a deletion of 
three bases (TCA) at position 1,439–41 (Fig. 2 D), which makes 
amino acid del455 in-frame (I455del). This residue corresponds 
to the first amino acid of the helicase domain III of XPD 
(Fig. 3 A; Gorbalenya and Koonin, 1993). Altogether, these 
results demonstrate that patients AS552 and AS553 have the 
XPD point mutation R683W on one allele and the new I455del 
mutation on the other allele. This mutation was also found in 
the AS551 cells from the father (Fig. 2 E and not depicted).
Clinical features differ among patients who are compound 
heterozygotes for the XPD R683W mutation
The clinical manifestations of the AS552 and AS553 patients 
were compared with those of other XP patients who are com-
pound  heterozygotes  for  R683W  and  a  second  mutation   
TTD (Kraemer et al., 2007). Primarily defined as a DNA repair 
syndrome (van Steeg and Kraemer, 1999), XP is characterized 
by a deficiency of the NER pathway, which leads to skin sun 
sensitivity. XP may also be caused by defects in other genes in 
the NER pathway (XPA, XPB/ERCC3, XPC, XPE/DDB2, 
XPF/ERCC4, or XPG/ERCC5) or in the polymerase eta gene 
(XP variant; Masutani et al., 1999; Lehmann, 2003; Kraemer   
et al., 2007). XP patients have a 1,000-fold increased frequency 
of skin cancers, including melanomas, squamous cell carcino-
mas, and basal cell carcinomas (Kraemer et al., 1987, 1994). 
Approximately 30% of XP patients, in addition, have progres-
sive neurological degeneration. Immature sexual development 
and dwarfism has been reported in a few XP patients (de Boer 
and Hoeijmakers, 2000), some of which may be associated with 
hormonal dysfunctions (Chen et al., 2002; Keriel et al., 2002; 
Drané et al., 2004; Compe et al., 2005, 2007).
The fact that most patients with XPD mutations are com-
pound heterozygotes complicates the understanding of geno-
type/phenotype relationships. For instance, the point mutation 
R683W in the XPD protein, a hotspot for the XP phenotype, 
is found as a heterozygous mutation in >80% of XP-D pa-
tients (Taylor et al., 1997; Kobayashi et al., 2002; Boyle et al., 
2008; Emmert et al., 2009). Curiously, the clinical manifesta-
tions of patients who are compound heterozygotes for XPD/
R683W and a second mutation include patients with or with-
out skin cancers and patients with or without severe neuro-
logical impairments (Taylor et al., 1997; Boyle et al., 2008; 
Emmert et al., 2009). This prompted us to study whether the 
mutation found on the second XPD allele might contribute to 
the heterogeneity of the clinical features.
In this study, we report XP patients in three families each 
carrying R683W with a different second XPD mutation and 
having different clinical symptoms. Two brothers with XP with 
cancers and neurodegeneration are compound heterozygotes for 
XPD R683W and an in-frame deletion of 1 aa (I455del). An-
other patient had >300 skin cancers and progressive neurode-
generation with R683W and a second mutation that leads to a 
premature stop codon (Q452X). Two siblings in the third family 
had  neither  skin  cancer  nor  neurodegeneration  and  carried 
R683W along with mutations leading to insertion of 2 aa 
(199insPP). We show how each of these second XPD mutations 
found in patients who also have the R683W mutation specifi-
cally interfere with TFIIH repair and transcription functions in 
vivo and in vitro. Together, our results suggest that the muta-
tions found on the second XPD allele participate along with 
R683W in the development of the XP phenotype.
RESULTS
Identification of new XP-D patients
Patients AS552 (Fig. 1, A and B) and AS553 (Fig. 1, C and D) 
were French brothers with XP who had clinically normal non-
consanguineous parents (AS550, mother; AS551, father; Table I, 
family 2).  In addition to burning on minimal sun exposure, they 
had several skin cancers (including malignant melanoma and ba-
sal cell carcinoma). They developed progressive neurodegener-
ation resulting in loss of ability to walk, talk, and swallow. JEM VOL. 206, December 21, 2009 
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(Fig. 1 G), had the same mutations and a similar mild XP phe-
notype (Table I; Boyle et al., 2008). Patient XP34BE never 
developed skin tumors, despite marked sun sensitivity on   
minimal sun exposure. He had excellent sun protection and 
developed only minimal freckle-like pigmentation on his face   
(Fig. 1 F). By age 31 yr he had no evidence of neurological ab-
normalities. Altogether, these observations clearly illustrate that 
XP patients who are compound heterozygotes and share the 
XPD point mutation R683W can have a wide spectrum of se-
verity with respect to their clinical phenotypes (Table I).
XPD mutations do not affect the TFIIH cellular 
concentration
The aforementioned data prompted us to analyze whether 
the mutations found on the second XPD allele contribute to 
(Table I). Patient XP29BE (with a premature stop codon 
Q452X on the other XPD allele; Fig. 3 A) was a Caucasian 
male with severe XP phenotype (Fig. 1 E; Kraemer et al., 
1988; Wang et al., 2009). In addition to severe sunburning on 
minimal sun exposure, and extensive freckle-like pigmenta-
tion, he had >300 skin cancers documented, including 24 cu-
taneous melanomas, 284 basal cell carcinomas, and 12 squamous 
cell carcinomas. He developed progressive neurological de-
generation with sensorineural deafness and severe motor im-
pairment (difficulty walking, talking, and swallowing). He died 
at age 39 yr of progressive neurological degeneration.
Patient XP34BE (bearing a mutation generating a frame 
shift after 2-aa PP insertion at position 199 on the other XPD 
allele, Fig. 3 A) is a Caucasian male with a mild XP phenotype 
(Fig. 1 F; Boyle et al., 2008). His sister, patient XP35BE   
Figure 1.  XP patients studied. (A and B) Patient AS552. (A) At 11 yr of age he had marked freckle-like hyperpigmentation in sun exposed portions of 
his face and neck. (B) By age 33 yr he used a wheelchair because of his inability to walk. He died at age 39 yr of progressive neurological degeneration.  
(C and D) Patient AS553, brother of AS552. (C) At 7 yr of age he had marked freckle-like hyperpigmentation in sun exposed portions of his face. (D) By  
29 yr of age he used a wheelchair because of his inability to walk. He had posturing of his hands, a feature of neurodegeneration. He died at age 35 yr of 
progressive neurological degeneration. (E) Patient XP29BE at 32 yr of age. He has marked freckle-like hyperpigmentation in sun exposed portions of his 
face and neck. His face shows extensive scarring and grafting from numerous surgical procedures for removal of skin cancers. The circled lesions on his 
face and shoulder were being followed photographically for signs of skin cancer. His conjunctiva show telangiectasia. He died at age 37 yr of progressive 
neurological degeneration. (F) Patient XP34BE. He was well protected from sun exposure and at age 24 yr he had minimal freckle-like hyperpigmentation 
on his face and neck and no skin cancers. By age 31 yr he had no evidence of neurological degeneration. (G) Patient XP35BE, younger sister of patient 
XP34BE. She was well protected from sun exposure and at age 20 yr she had minimal freckle-like hyperpigmentation on her face and neck and no skin 
cancers. Brief sun exposure of an unprotected portion of her neck resulted in an acute sunburn followed by hyperpigmentation, scaling and peeling of the 
skin (arrow). By age 27 yr she had no evidence of neurological degeneration.3034 Biallelic effects in XP-D patients | Ueda et al.
Mutations in XPD alter its helicase activity  
and the composition of TFIIH
We next analyzed whether the mutated XPD had an effect 
on the TFIIH architecture, as some XPD mutations weaken 
the interaction between XPD and the p44 subunit, which 
anchors the CAK to the core of TFIIH (Coin et al., 1998). 
The mutated forms of XPD were tagged with either a Histidine-
tag (His-XPD/WT, /R683W, /Q452X, and /199insPP) or 
a Flag-tag (Flag-XPD/WT and /I455del) and then expressed   
in Sf9 cells by using the baculovirus expression system. The 
size and extent of expression of each mutated form of XPD 
was verified by Western blots by using antibody raised against 
either the His- or the Flag-tag (Fig. 4 A).
Recombinant TFIIH complexes (rIIH), resulting from 
coinfection by baculoviruses containing the XPD mutated 
forms found in patients together with baculoviruses express-
ing each of the other subunits of TFIIH, were produced in 
Sf9 cells (Dubaele et al., 2003) and then immunoprecipitated 
by using antibody directed toward the p44 subunit. Under 
low-salt conditions (50 mM KCl), the XPD/R683W, /Q452X, 
/199insPP, and /I455del coimmunoprecipitated with all the 
other subunits of TFIIH (Fig. 4 B). Strikingly, at higher 
salt concentration (150 mM) the composition of the immuno-
precipitated rIIH containing the XPD/WT, /R683W, /Q452X, 
and /I455del was maintained (Fig. 4 C, lanes 1–3 and 5–6). 
However, we failed to obtain an entire XPD/199insPP rIIH 
(lane 4). Indeed, neither the CAK subcomplex (illustrated by 
cdk7 and cyclin H) nor the truncated XPD/199insPP co-
immunoprecipitated at 150 mM KCl. Collectively, the above 
data indicate that XPD mutations affect the stability of TFIIH 
in different ways.
Knowing that XPD contributes to the anchoring of   
the CAK subcomplex to the core of TFIIH, we analyzed 
whether XPD mutations impede its interaction with p44 
the clinical phenotype. Some XPD mutations disrupt the 
steady-state TFIIH levels in cells derived from TTD patients 
(Vermeulen et al., 2000; Botta et al., 2002; Boyle et al., 2008). 
We thus analyzed the TFIIH cellular concentration in fibro-
blasts  isolated  from  the  compound  heterozygous  XPD/
R683W patients (Fig. 3 B). Whole-cell extracts isolated from 
WT FB789 and AS550 cells (used as controls), as well as from 
XP34BE, XP29BE, and AS552 fibroblasts were resolved by 
SDS-PAGE. We found that the TFIIH cellular concentra-
tion (as indicated by the Western blotting of its XPB, XPD, 
p62, p52 and cdk7 subunits) is similar in XPD and normal 
cells using -tubulin as a reference. It is worthwhile to note 
that the premature truncated forms of XPD/Q452X (molec-
ular weight [MW] = 53 kD, lanes 4–6) and XPD/199insPP 
(MW = 28 kD, lanes 7–9) cannot be visualized in XP34BE 
and XP29BE cells, respectively, because the only available 
antibody recognizes an epitope located within the C-terminal 
part of XPD. To analyze whether the XPD-mutated forms 
might be found in vivo in the TFIIH complex, eukaryotic 
expression vectors encoding either WT or the mutated forms 
of XPD with a Flag-tag were generated and transiently trans-
fected into HD2 cells. HD2 cells are a cell line resulting from 
the fusion between human fibroblasts harboring the XPD/
R683W point mutation and HeLa cells (Johnson et al., 1985). 
We performed chromatin immunoprecipitation (ChIP) with 
an antibody directed against XPB (Ab-XPB). Western blot 
analysis revealed that XPD/WT, /Q452X, /199insPP, and 
/I455del fusion proteins coimmunoprecipitated together with 
XPB, p62, p44, and cyclin H subunits of TFIIH (Fig. 3 C). 
Together, these results indicate that the XPD mutations 
found in XP patients who are compound heterozygotes for 
R683W and a second mutation do not alter the steady-state 
cellular concentration of components of TFIIH or the binding 
of this complex to chromatin.
Table I.  Clinical features and XPD mutations of patients studied
XPD mutations
allele1 allele2  allele2 allele2
Family Patient Age/sex Living/
dead
Acute sun 
sensitivitya
Skin 
cancer
Progressive 
neurological 
abnormalities
R683W Q452X I455del 199insPP References
1 XP29BE 37 yr/M dead +b +c,d +b + + Kraemer et al.,1988e; 
Wang et al., 2009; this 
study
2 AS552 39 yr/Mf dead + +c + + + This study
2 AS553 35 yr/Mf dead + +c + + + This study
3 XP34BE 31 yr/Mg alive + 0 normal + + Boyle et al., 2008
3 XP35BE 27 yr/Mg alive + 0 normal + + Boyle et al., 2008
aSkin burning on minimal sun exposure.
bPresent.
cIncluding at least one melanoma.
d>300 documented skin cancers, including 24 melanomas, 284 basal cell carcinomas, and 12 squamous cell carcinomas.
eXP29BE was patient 7 in this study.
fSiblings.
gSiblings.JEM VOL. 206, December 21, 2009 
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(Dubaele et al., 2003). Equal amounts of either WT or mu-
tated XPD subunits were incubated with or without p44 
(when indicated) in the presence of Ab-p44 cross-linked to 
agarose beads (Fig. 4 D). After extensive washing at high-salt 
concentration (350 mM KCl), we observed that p44 is able 
to retain much less XPD/R683W and XPD/I455del than 
XPD/WT (Fig. 4 D, compare lanes 1 and 3 and compare 
lanes 2 and 6), whereas no XPD binding was found in ab-
sence of p44 (Fig. 4 D, lanes 7–12). Strikingly, the truncated 
XPD/Q452X and XPD/199insPP did not coimmunopre-
cipitate with p44 (Fig. 4 D, lanes 4 and 5), which is not sur-
prising  because  p44  interacts  with  the  C-terminal  end  of 
XPD (Coin et al., 1998). Our data show how each of the 
mutations of the XPD helicase specifically affect its interac-
tion with the p44 subunit of TFIIH.
XPD mutations inhibit NER activity
XPD is crucial for the functioning of TFIIH in DNA repair 
(Schaeffer et al., 1993; Drapkin et al., 1994). We thus inves-
tigated the effect of the XPD mutations in in vitro NER as-
says. The rIIHs (immunoprecipitated at 50 mM KCl; Fig. 4 B) 
were tested in a dual-incision assay using the purified NER 
factors and damaged plasmid containing a single cisplatin 
adduct (Araújo et al., 2000). Whereas the rIIH XPD/WT   
potentiates the removal of the damaged oligonucleotides 
when added to the reaction (Fig. 5 A, lanes 1–2 and 9–10; 
Fig. S1 A shows the complete gel), rIIH-XPD/R683W,   
/Q452X, /199insPP, and /I455del were inactive (Fig. 5 A, 
lanes 3–8 and 11–12).
This prompted us to analyze whether the XPD muta-
tions would affect either the helicase and/or the ATPase 
activity of XPD. The 5-3 XPD helicase activity was mea-
sured with an in vitro assay that detects the displacement of 
a 32P-labeled DNA fragment previously annealed to a single-
stranded circular DNA (Schaeffer et al., 1993). When added 
to the in vitro assay, rIIH (immunoprecipitated at 50 mM 
salt concentration) containing XPD/Q452X, /199insPP, or 
/I455del did not displace the labeled oligonucleotide from 
the single-stranded plasmid (Fig. 5 B, lanes 5–8 and 11–12; 
Fig. S1 B shows the complete gel). In this case, we also ob-
served that rIIH-XPD/R683W exhibits a lower helicase 
activity than rIIH-XPD/WT (reduction of 40 ± 2%; com-
pare Fig. 5 B, lanes 3–4 to 1–2). We next investigated the 
ATPase activity of the XPD-mutated forms (Fig. 5 C). The 
WT and mutated XPD proteins were immunoprecipitated, 
extensively washed at 500 mM NaCl, and incubated in   
the presence of [-32P]ATP and double-stranded DNA. 
We  observed  that  the  ATPase  activity  of  the  mutated 
forms of XPD was not affected. This result was anticipated 
because the ATP binding site of XPD is located at position 
Figure 2.  Identification of the XPD mutations in the AS550 and 
AS552 patients. (A) Host cell reactivation in AS550 (filled columns) and 
AS552 (open columns). Fibroblasts were transfected with the pCMV-luc 
(500 ng) previously exposed to 1,000 J/cm2 of UVC-light (254 nm), 
pCH110 (100 ng, encoding the -galactosidase which was used to nor-
malize transfection efficiencies), and either empty pcDNA (10 ng; left pair 
of columns) or pcDNA XPD WT (10 ng, XPD WT; right pair of columns). 
Host cell reactivation was measured as the relative luciferase activity 
caused by the repair of the UV-damaged luciferase gene. The values of 
three independent experiments are presented as percentages, 100% being 
the level of luciferase activity obtained in AS550 cells. (B) Scheme repre-
senting the PCR products obtained from XPD allele with or without the 
point mutation R683W, which corresponds to a C-to-T substitution at the 
first base of exon 22 in the gene. This mutation abolishes the restriction 
site for the endonuclease MspA1l. (C) PCR products were obtained from 
genomic DNA of AS550, AS551, AS552, AS553, and FB789 (used as con-
trol) fibroblasts. Restriction fragment length polymorphism assay was 
performed from the PCR products digested by MspA1l. (D) DNA sequenc-
ing of the PCR product obtained from cDNA of AS552 cells. The XPD allele 
without the R683W point mutation has a deletion of three bases (TCA) at 
position 1439–41, giving rise to an amino acid del455 in-frame (I455del). 
(E) Genetic pedigree of the family of the patients AS552 and AS553. The 
mother AS550 (I-1) carries the XPD mutation that corresponds to an 
amino acid substitution at position R683W. The father AS551 (I-2) carries 
a deletion of three bases (TCA) at position 1439–41 that makes amino 
acid del455 in-frame (I455del). The deceased patients AS552 (II-1) and his 
brother AS553 (II-2) had compound heterozygous mutations that corre-
sponded to the substitution at R683W (maternal) and the deletion I455del 
(paternal), resulting in the development of XP with skin cancer and neu-
rological degeneration.
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Figure 3.  TFIIH complex into XPD fibroblasts. (A) The diagram represents the 760-aa XPD protein with the 7 (I–VI) helicase motifs. Amino acid 
changes resulting from mutations found in the XPD/R683W patients who are compound heterozygotes are depicted. (B) Western blot analyses of TFIIH 
subunits (XPB, XPD, p62, p52, and cdk7) in increasing amounts of whole-cell extracts isolated from fibroblasts of FB789, XP34BE, XP29BE, AS550, and 
AS552 patients. * indicate nonspecific bands. -Tubulin ( tub) was used as an internal control. The results are representative of three independent ex-
periments. Diagram represents the ratio between each TFIIH subunit and  tub (arbitrary units). (C) Western blotting analysis of Ab-XPB ChIP (IP XPB) 
samples from chromatin extracts isolated from HD2 cells transfected with expression vectors encoding either Flag-XPD/WT (80 kD), /Q452X (53 kD), 
/199insPP (28 kD), or /I455del (80 kD). The immunoprecipitated fractions were resolved on SDS-PAGE followed by immunoblotting using antibodies 
raised against XPB, p62, p44, cyclin H and the Flag-tag. In vitro synthesized Flag-XPD mutated proteins (IVT Flag XPD, lanes 1 to 4) and highly purified 
TFIIH from HeLa cells (lane 5) were used as references. Arrows indicate the different forms of XPD. * indicate nonspecific bands. The results are represen-
tative of three independent experiments.JEM VOL. 206, December 21, 2009 
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XPD mutations inhibit basal transcription activity
The rIIHs were next tested for their transcription activity. 
When added to an incubation mixture containing the AdMLP 
template, RNA pol II, and the basal transcription factors 
(Dubaele et al., 2003), rIIH-XPD/R683W exhibit a tran-
scription activity as strong as rIIH-XPD/WT (Fig. 6 A, lanes 
3–4 and 1–2, respectively; see Fig. S2 A for the complete gel). 
K48 and should not be altered by these mutations (Sung   
et al., 1988).
Taken together, the above results clearly demonstrate that 
mutations found in XP patients who are compound hetero-
zygotes for R683W and a second mutation affect the TFIIH 
activity during NER by disturbing the helicase function of 
XPD without affecting its ATPase activity.
Figure 4.  XPD mutations disrupt TFIIH integrity. (A) Production in SF9 insect cells of the recombinant mutated forms of XPD tagged with either the His-
tag (His-XPD/WT, /R683W, Q452X, and 199insPP) or the Flag-tag (Flag-XPD/WT and /I455del). Whole-cell extracts were resolved by SDS-PAGE and blotted 
with antibodies raised against either the His- or the Flag-tag. Arrows indicate the theoretical molecular weight of each XPD mutated form. The results are 
representative of four independent experiments. (B) Purification of the recombinant TFIIH (rIIH). Insect cells were infected with baculoviruses overexpressing 
the subunits of TFIIH including either WT or mutated XPD, and complexes were immunoprecipitated by using antibody (Ab) directed toward the p44 subunit 
of the core TFIIH in low salt conditions (50mM KCl). After elution with a synthetic peptide recognized by Ab-p44, equal amounts of purified rIIHs were then 
resolved by SDS-PAGE and blotted with antibodies against XPB, p62, p52, cdk7 and cyclin H subunits of TFIIH. His-XPD/WT, /R683W, /Q452X, /199insPP, and 
Flag-XPD/WT, /I455del were visualized with antibodies raised against either the His- or the Flag-tag, respectively. Arrows indicate the different forms of XPD. 
The results are representative of five independent experiments. (C) Immunoprecipitation with Ab-p44 of the various rIIH in a higher salt condition (150 mM 
KCl). rIIHs immunoprecipitated with Ab-p44 cross-linked on agarose beads were boiled, resolved by SDS-PAGE, and blotted with antibodies against p62, cdk7, 
cyclin H, and either the His- or the Flag-tag. Arrows show the different forms of XPD. HC., heavy chain of Ab-p44; LC, light chain of Ab-p44; * indicates a 
nonspecific band. The results are representative of three independent experiments. (D) Infected Sf9 cell lysates containing either WT or mutated XPD as indi-
cated at the top of the panel, were incubated with (+ p44) or without ( p44) WT p44, immunoprecipitated to agarose beads and further washed with  
350 mM KCl. The immunoprecipitated fractions were then resolved on SDS-PAGE, followed by immunoblotting using Ab-p44 and either anti-His or anti-Flag 
antibodies. * indicates a nonspecific band. The results are representative of three independent experiments.3038 Biallelic effects in XP-D patients | Ueda et al.
The phosphorylation of the C-terminal domain (CTD) of 
the largest subunit of RNA pol II by the cdk7 subunit of TFIIH 
is a prerequisite to allow the transition between initiation and 
elongation and further promoter escape (Akoulitchev et al., 
1995; Dvir et al., 1997). We thus checked the phosphorylation 
status of RNA pol II after the in vitro transcription. Antibody 
that recognizes the hypo- (IIA) and hyperphosphorylated (IIO) 
forms of the largest subunit of RNA pol II showed that the 
phosphorylation status of the RNA pol II was similar when 
rIIH-XPD/WT  and  /R683W  were  present  in  the  assay 
(Fig. 6 B, compare lanes 1–2 and 3–4, respectively; Fig. S2 B 
shows the complete gel). However, we observed the lack of 
RNA pol IIO in the presence of either rIIH-XPD/199insPP 
or rIIH-XPD/I455del (Fig. 6 B, lanes 7–8 and 11–12). More-
over, the phosphorylation of RNA pol II was not totally   
abrogated by rIIH-XPD/Q452X (Fig. 6 B, lanes 5–6; see Dis-
cussion). Having observed that some of the mutated rIIHs pre-
vent the phosphorylation of the CTD of RNA pol II in the 
context of a transcription assay, we next investigated whether 
the XPD mutations disturb the enzymatic activity of the cdk7 
kinase itself. In vitro kinase assays show that rIIH-XPD/
R683W, /Q452X, and /I455del, as well as rIIH-XPD/WT, 
phosphorylated the CTD fused to the GST protein (Fig. 6 C, 
compare lanes 3–4 to lane 2 and lane 7 to lane 6; Fig. S2 C 
shows the complete gel). On the contrary, rIIH-XPD/199insPP 
did not phosphorylate CTD (Fig. 6 C, lane 5).
We  thus  investigated  how  transcription  occurs  in  the 
presence of the combinations of TFIIH found in the XP-D 
patients. rIIH XPD/R683W, rIIH XPD/Q452X, /199insPP, 
or /I455del were preincubated either alone or in combina-
tion, in the presence of RNA pol II, the general transcrip-
tion factors (GTF), the AdMLP template, ATP, and CTP 
(Fig. 6 D). 15 min later, the transcription process was initi-
ated by addition of GTP and UTP (Fig. 6 D, see proto-
col scheme). rIIH XPD/R683W had greater transcription 
activity than rIIH XPD/Q452X, /199insPP, or /I455del 
separately.Furthermore, rIIH XPD/Q452X, /199insPP, and 
/I455del did not counteract the transcription activity when 
combined with rIIH XPD/R683W. In contrast, we observed   
an additive effect. Similar results were obtained when we per-
formed transcription assays with preincubation of rIIH XPD/
Q452X, /199insPP and /I455del before addition of rIIH XPD/
R683W (unpublished data).
Impaired transactivation of nuclear receptors in XP-D cells
TFIIH is involved in the transactivation of nuclear receptors by 
phosphorylating (via its cdk7 kinase subunit) either their A/B 
domain (as shown for ER, PPAR, or RAR; Rochette-Egly 
et al., 1997; Chen et al., 2002; Compe et al., 2007) or one of 
their partners (such as Ets1 for the vitamin D receptor; Drané 
et al., 2004). We thus analyzed by real-time quantitative 
RT-PCR the expression of genes known to be under the   
control of nuclear receptors in fibroblasts isolated from the 
compound  heterozygote  XPD/R683W  patients  (XP34BE, 
XP29BE, and AS552) and from the homozygous XPD/R683W 
patient (XP135LO; Taylor et al., 1997), as well as from normal 
On the contrary, rIIH-XPD/Q452X, /199insPP, and /I455del 
result in barely detectible in vitro RNA synthesis (Fig. 6 A, 
lanes 5–8 and 11–12).
Figure 5.  DNA Repair Activities of the rIIHs. (A) Equivalent increas-
ing amounts of rIIHs (adjusted according to Western blotting) were added 
to an incision/excision assay using recombinant NER factors. The area of 
the gel containing the excision products is shown (the complete gel is 
shown in Fig. S1 A). The excised oligonucleotides signals were quantified 
and plotted in arbitrary units (au). The results are representative of three 
independent experiments. (B) Helicase activity of the WT and mutated 
forms of XPD. Equivalent increasing amounts of the various immunopre-
cipitated rIIH were tested for their 5–3 XPD helicase activity. The density 
of radiolabeled oligo displaced by the XPD helicase activity was measured 
and plotted in arbitrary units (au). The results are representative of three 
independent experiments. The complete gel is shown in Fig. S1 B.  
(C) Equal amounts of immunoprecipitated XPD were tested in an ATPase 
assay for 120 min. Nonhydrolyzed ATP as well as Pi are indicated. The ATP 
hydrolysis was quantified and plotted in arbitrary units (au). The results 
are representative of three independent experiments.JEM VOL. 206, December 21, 2009 
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Figure 6.  Transcription activity of the rIIHs. (A) Basal transcription activity of the rIIHs. The purified rIIHs were added to an in vitro reconstituted 
transcription system lacking TFIIH. The length of the corresponding transcript is indicated on the left side. The transcription activity of all variants was 
assessed using increasing amounts of rIIHs for 30 min. The signals were quantified and plotted in arbitrary units (au). The results are representative of 
three independent experiments. The complete gel is shown in Fig. S2 A. (B) Phosphorylation of the RNA polymerase II during in vitro reconstituted tran-
scription assays. The RNA pol II kinase activity of low salt immunopurifed rIIHs was analyzed in an in vitro assay containing all the basal transcription 
factors and the AdMLP. Arrows indicate hypo (IIA) and hyper (IIO) phosphorylated forms of RNA pol II. The results are representative of two independent 
experiments. The complete gel is shown in Fig. S2 B. (C) In vitro phosphorylation of the GST-CTD fusion protein was performed with equal amounts of 
rIIHs in the presence of 0.14 µM [-32P] ATP. Coomassie blue–stained gel (staining; top) and autoradiography (autoradio; bottom) of the incubated frac-
tions are shown. The results are representative of three independent experiments. The complete gels are shown in Fig. S2 C. (D) In vitro reconstituted 
transcription assays were performed following the protocol scheme. rIIH XPD/R683W, rIIH XPD/Q452X, /199insPP, or /I455del were preincubated either 
alone or in combination, in the presence of RNA pol II, the general transcription factors (GTF), the AdMLP template, ATP, and CTP. 15 min later, the tran-
scription process was initiated by addition of GTP and UTP. The reactions were performed for 15 and 30 min. The signals of three independent experi-
ments were then quantified and plotted in arbitrary units (au).3040 Biallelic effects in XP-D patients | Ueda et al.
fibroblasts (FB789) and from an XPD/R683W heterozygote 
(AS550; Fig. 2 C). We first examined the expression of a vitamin 
D nuclear receptor (VDR) target gene, vitamin D-24-hydroxy-
lase (CYP24; Akeno et al., 1997), and the osteopontin gene whose 
expression  is  known  to  be  unaltered  in  XPD-deficient  cells 
(Drané et al., 2004). Upon induction by vitamin D (100 nM), 
the expression of CYP24 (Akeno et al., 1997) was much lower 
in the XPD-deficient fibroblasts than in WT cells (Fig. 7 A, up-
per panel). Moreover, we particularly noticed that the CYP24 
expression shows a greater reduction in XP29BE than in 
XP34BE, XP135LO, or AS552 fibroblasts. In contrast, the ex-
pression of the osteopontin gene was unaltered in any of the XPD-
deficient cells (Fig. 7 A, bottom), suggesting that the expression 
of some genes can normally occur in these XPD-deficient cells.
Figure 7.  Incidence of XPD mutations during the transactivation mediated by nuclear receptors. (A) Expression of the VDR target genes CYP24 
and osteopontin in WT (FB789, AS550) and XPD mutated (XP34BE, XP29BE, XP135LO, AS552) fibroblasts after treatment during 8h with vitamin D (vit. D, 
100 nM). The values were normalized relative to 18S RNA expression. The results of three independent experiments are presented as n-fold induction 
relative to nontreated cells. (B) Expression of the TR target gene KLF9 in FB789, XP34BE, XP29BE, XP135LO, AS550, and AS552 fibroblasts after treatment 
during 24 h with T3 (10 nM). The values were normalized relative to 18S RNA expression. The results of three independent experiments are presented as 
n-fold induction relative to nontreated cells. (C) Recruitment of RNA pol II, TFIIH, and TR on the KLF9 promoter. After T3 treatment, the recruitment of 
RNA pol II and TFIIH (via its p44 subunit) was analyzed by ChIP assays on the KLF9 proximal promoter. The TR recruitment was studied on a TRE located at 
2.9 kb in the KLF9 promoter. The results of three independent experiments are presented as percentage of DNA immunoprecipitated relative to the in-
put; und, undetectable. (D) DNase1 footprint analysis on the TRE located into the TR target gene mbp. The MBP fragment (256/+21) was labeled at the 
5 end and incubated with TR1 and increasing amounts of rIIH XPD/WT (lanes 8–9), /R683W (lanes 10 and 11), /Q452X (lanes 12 and 13), /199insPP 
(lanes 14 and 15), and /I455del (lanes 16 and 17). Cis-element for the TRs (from nt-184 to nt-167) is positioned. Autoradiography of the gel is shown 
from nt-200 to nt-150. Graph depicts the protection level on the MBP-TRE (see Materials and methods). The complete gel is shown in Fig. S3 A.JEM VOL. 206, December 21, 2009 
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Collectively, our results demonstrate that the transactiva-
tion mediated by nuclear receptors is differentially affected in 
cells isolated from several patients who are compound het-
erozygotes for R683W/XPD and a second mutation. Strik-
ingly, such defects result from deficiencies in the recruitment 
of the basal transcription machinery and the nuclear recep-
tors, in which the product of the second XPD allele might   
be implicated.
DISCUSSION
Marked heterogeneity of clinical features is observed in XP 
patients who are compound heterozygotes for XPD/R683W 
and a second mutation (Table I). Because some putative bial-
lelic effects might be difficult to distinguish from the influ-
ence of environment and genetic background, we engaged a 
systematic study of the incidence of XPD mutations on the 
numerous TFIIH functions during NER and transcription 
(Table II).
We designed recombinant rIIH XPD/R683W, /Q452X, 
/I455del, and /199insPP in which the XPD subunit carries 
different amino acid changes found in XP patients who are 
compound heterozygotes for XPD/R683W and a second 
mutation, and have different clinical symptoms. Each of the 
recombinant TFIIH mutants exhibited unique biochemical 
properties (Table II). None of them displayed in vitro DNA 
repair (NER) activity (Fig. 5 A). All the mutations inhibited 
the 5–3 helicase activity of XPD, except the point mutation 
R683W. The XPD/R683W mutant, however, exhibited a 
much lower helicase activity when compared with XPD/
WT. It seems that XPD mutations affect the helicase activity 
either by altering the helicase domain (the mutation I455del 
is  located  in  the  helicase  motif  III,  whereas  Q452X  and 
199insPP generate truncated forms) or by disrupting the in-
teraction between the XPD CTD and the regulatory p44 
subunit within TFIIH (such as the point mutation R683W, 
Fig. 4 D). We also noticed that all the mutations retained the 
ATPase activity of XPD, which was not surprising because 
these mutations do not affect the ATP binding site (Sung 
et al., 1988). However, our results for human XPD/R683W 
differ from those reported for an archeobacteria homologue 
of XPD bearing the same mutation (Fan et al., 2008). Besides 
the fact that these proteins come from different organisms, 
this apparent discrepancy might also be explained by the na-
ture of the DNA substrate used in the ATPase assays (double-
stranded versus single-stranded DNA; Singleton et al., 2007). 
We next observed that rIIH XPD/Q452X, /I455del, and 
/199insPP were highly defective during in vitro transcription 
assays that only contained the minimal set of basal transcrip-
tion factors in addition to the RNA pol II. Under our in vi-
tro experimental conditions, the RNA synthesis was similar 
in the presence of rIIH XPD/R683W to that observed with 
rIIH XPD/WT (Fig. 6 A), underlying the fact that the XPD 
unwinding activity is not essential for transcription (Dubaele 
et al., 2003; Coin et al., 2007).
In dissecting which molecular processes were affected   
during RNA synthesis, we found that each XPD mutation   
We also examined the expression of Krüppel-like factor 9 
(KLF9; Fig. 7 B), a thyroid hormone receptor (TR) respon-
sive gene in human fibroblasts (Moeller et al., 2005). After   
24 h of treatment with triiodothyronine T3 (10 nM), the ex-
pression of KLF9 was clearly reduced in the XPD-mutated 
fibroblasts when compared with WT. Moreover, similar to 
that observed for the vitamin D target gene CYP24 (Fig. 7 A), 
the expression of KLF9 showed a much greater reduction in 
XP29BE than in XP34BE, AS552, or XP135LO fibroblasts. 
It should be noted that expression of these genes in cells 
from the compound heterozygote XPD/R683W patients 
(XP34BE, XP29BE, and AS552) was different from that in 
the homozygous XPD/R683W patient (XP135LO).
Chromatin immunoprecipitation (ChIP) assays were then 
undertaken to investigate whether the expression pattern of 
the KLF9 gene in XPD-deficient cells could be correlated 
with transcriptional defects (Fig. 7 C). The genomic DNA 
fragments bound to RNA pol II and TFIIH were immuno-
precipitated with corresponding antibodies and were further 
analyzed by quantitative (q)PCR with primers designed to 
amplify the transcription initiation start site of the KLF9 pro-
moter (from – 41 to +39). After 24 h of treatment with triio-
dothyronine T3 (10 nM), the recruitment of RNA pol II as 
well as of TFIIH was clearly reduced in the XPD mutated fi-
broblasts when compared with that observed in the corre-
sponding WT cells. Antibodies directed against TR were also 
used to immunoprecipitate DNA fragments encompassing a 
thyroid hormone response element (TRE) located in the dis-
tal KLF9 promoter (from 2,891 to 2,875; Denver and 
Williamson, 2009). After T3 treatment, we clearly observed 
that the TR recruitment on the TRE was reduced in the 
XPD-mutated fibroblasts when compared with WT (Fig. 7 C, 
bottom), suggesting that the lower amounts of mRNA ob-
served in the mutated cells (Fig. 7 B) are caused by defects at 
a transcriptional level.
TFIIH contributes to the binding stability of the nuclear 
receptors on their response elements (Compe et al., 2007), 
thus we analyzed whether the XPD mutations might affect 
such coactivator function of TFIIH. The proximal promoter 
of the myelin basic protein (mbp) gene, which is known to con-
tain a response element for the TRs (from nt-184 to nt-167; 
Farsetti et al., 1991), was used as a radiolabeled probe during 
DNase1 in vitro footprinting assays (see Materials and meth-
ods).  The  radiolabeled-mbp  promoter  was  incubated  with 
highly purified TR1 in the presence of either rIIH-XPD/
WT, /R683W, /Q452X, or /I455del (Fig. 7 D; Fig. S3 A 
shows the complete gel). Whereas the rIIH complexes did 
not modify the pattern of digestion by the DNase1 of the mbp 
promoter in absence of TR1 (Fig. 7 D, compare lanes 2–6   
to lane 1), we observed that increasing amounts of rIIH 
XPD/WT, /R683W, /Q452X, and /I455del similarly pro-
mote the recruitment of TR1 on its response element TRE 
(Fig. 7 D, lanes 7–13). Strikingly, we found that rIIH XPD/
199insPP, which affects the TFIIH architecture (Fig. 4 C), does 
not efficiently stabilize TR1 on its TRE (Fig. 7 D, compare 
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alleles (Taylor et al., 1997; Cleaver et al., 1999). In support of 
this hypothesis, some analogous XPD mutations in Schizosac-
charomyces pombe rad15 failed to support viability in the hap-
loid  state  and  were  thus  considered  devoid  of  signficant 
biological activity. However, XP, XP/Cockayne syndrome, 
TTD, or XP/TTD patients who are compound heterozy-
gous for the same XPD causative mutation develop different 
clinical features (Table I; Broughton et al., 2001; Fujimoto 
et al., 2005; Rao et al., 2007; Botta et al., 2009), which is diffi-
cult to explain from a monoallelic assumption. Moreover, if 
the phenotype depended only on one XPD causative muta-
tion, there should not be striking differences between XPD/
R683W heterozygous and homo-/hemizygous patients. We 
clearly observed that each XPD mutation affected different 
functions of TFIIH (Table II). Gene expression was differ-
ently affected depending on the mutation found on the sec-
ond allele, indicating that, in absence of a WT allele, genetic 
interactions between recessive XPD alleles might result in 
different transcriptional outcomes. Thus, the induction of the 
KLF9  gene  by  T3  was  much  less  reduced  in  the  XPD 
R683W/Q452X compound heterozygous cells than in the 
XPD R683W homozygous, suggesting that the transactiva-
tion  defect  directed  by  XPD/R683W  might  be  partially 
counteracted by the XPD/Q452X. Conversely, the expres-
sion of the vit-D–induced CYP24 was similarly affected in 
the XPD R683W/199insPP cells when compared with that 
observed in the XPD/R683W homozygous cells, suggesting 
that the deficiency associated with XPD/199insPP might be 
complemented by XPD/R683W. This could be correlated 
with recent analyses of compound heterozygous mouse mod-
els showing a variety of biallelic effects, including interallelic 
complementation, a phenotype attributable to combinations 
of recessive XPD alleles (Andressoo et al., 2006). It is worth-
while to note that patients with XP or TTD with XPD splice 
mutations (as in XP34BE and XP35BE) may have mild symp-
toms in conjunction with a small amount of WT XPD mRNA, 
as previously described (Boyle et al., 2006; Botta et al., 2009). 
In addition, we cannot exclude that the XPD/199insPP 
differently weakens XPD/p44 interactions (Table II). Know-
ing that such interactions direct the anchoring of the CAK 
kinase complex, and consequently the positioning of TFIIH 
within the transcription complex, it is not surprising to observe 
that beside defect in basal transcription, each mutation will also 
differently affect the transactivation process. We thus found 
that rIIH XPD/199insPP and rIIH XPD/I455del failed to 
phosphorylate RNA pol II (Fig. 6 B), although the cdk7 kinase 
activity rIIH XPD/I455del was not directly disrupted by the 
mutation (Fig. 6 C and Table II). Interestingly, the CTD of the 
RNA pol II was correctly phosphorylated in the presence of 
rIIH XPD/Q452X during in vitro transcription as well as in 
vitro kinase assays (Fig. 6 B and 6C). These observations show 
that a given XPD mutation affects specific molecular processes 
during transcription, resulting in a different biochemical phe-
notype for each. These differences were more clearly illus-
trated in the in vivo transactivation assays. Indeed, we observed 
that the transactivation mediated by nuclear receptors, such as 
VDR, TR, and the retinoic acid receptors RAR (Fig. 7 A and 
7B, and unpublished data) was differently affected in the fibro-
blasts from different compound heterozygous XPD/R683W 
patients. Whereas the expression of some genes, such as the 
osteopontin, is unaltered in these cells (Fig. 7 A, lower panel; 
Drané et al., 2004), the severity of the transactivation defect 
depends on the nature of the mutation found on the second 
XPD allele. While dissecting the transactivation mechanism, 
by either ChIP or DNase1 in vitro footprinting assays (Fig. 7 
C and 7D), we observed that TR were differently recruited on 
the promoter of target genes and consequently were unable to 
transactivate properly their responsive genes. More precisely 
we demonstrated that TFIIH-XPD/199insPP does not fully 
stabilize TR on its response element (Fig. 7 D).
Although compound heterozygosity is common in hu-
man recessive disorders, its incidence in the development of 
disease such as XP has not been well established. XPD muta-
tions exclusively related to XP (such as XPD/R683W) were 
considered as causative mutations, and other alleles that were 
associated with more than one disorder were regarded as null 
Table II.  Summary of the effects of the different XPD mutations
XPD mutation
R683W Q452X I455del 199insPP
DNA repair NER
helicase activity ±
ATPase + + + +
TFIIH structure   50 mM KCl + + + +
150 mM KCl + + +
p44–XPD interaction                      350 mM KCl + +
Transcription RNA pol II phosphorylation + ±
cdk7 kinase activity + + +
basal transcription +
transactivation by nuclear receptors
nuclear receptor stabilization + + + ±JEM VOL. 206, December 21, 2009 
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ChIP Western blot assays. HD2 cells were grown in DME/HamF10 
(vol/vol) containing 10% FCS and 40 µg/ml gentamycin and were plated to 
50% confluency before transfection. The cells were then transiently trans-
fected using the transfection reagent JetPei (Polyplus-Transfection). In all 
experiments, 12 µg of each expression vector were used per 15-cm dish (6–8 
dishes were used for each expression vector). At 48 h after transfection, solu-
ble chromatin was prepared as previously described (Coin et al., 2008). In 
each assay, 750 µg of protein from cross-linked chromatin was immunopre-
cipitated with polyclonal antibodies raised against the p89 subunit of TFIIH 
(sc-293; Santa Cruz Biotechnology, Inc.). The immunocomplexes were 
collected overnight at 4°C by adsorption to protein A/G–Sepharose beads. 
The beads were next washed and resuspended in 1× Laemmli SDS buffer. 
Samples  were  incubated  at  95°C  for  90  min  for  de–cross-linking   
prior electrophoresis.
Construction of baculoviruses. Baculoviruses overexpressing XPB, p62, 
p52, p44, p34, cdk7, cyclin H, MAT1, and p8 were as previously described 
(Dubaele et al., 2003; Coin et al., 2007). cDNAs encoding the various mu-
tated XPD proteins were obtained by PCR site-directed mutagenesis and 
inserted into either the PVL1392 or the pSK278 vector. The resulting vec-
tors were recombined with baculovirus DNA (BaculoGold; PharMingen). 
The recombinant viruses were purified from isolated plaques and viral stocks 
were prepared by three-step growth amplification.
Purification of complexes. Sf9 insect cells were infected with Flag-XPB, 
WT or mutated XPD, p62, p52, p44, p34, Flag-cdk7, cyclin H, and Mat1 
baculoviruses. The whole-cell extracts were initially incubated 4 h, with 
agarose beads bound to anti–M2-Flag antibody at 4°C. After washing with a 
buffer containing 50 mM Tris/HCl (pH 7.9), 20% glycerol, and 50 mM 
KCl, rIIH9 complexes were eluted for 8–12 h with the same buffer contain-
ing 0.2 mg/ml of the epitope peptide (Jawhari et al., 2002). The eluted frac-
tion was then incubated with anti-p44 (1H5) antibody in a buffer containing 
50 mM Tris/HCl (pH 7.9), 20% glycerol, and either 50 or 150 mM KCl. 
The immunoprecipitated fraction was then either boiled or eluted with a 
synthetic peptide recognized by Ab-p44.
Interaction assays. WT or mutated XPDs were coexpressed with p44 by 
infecting Sf9 insect cells with the corresponding baculoviruses. Cell extracts 
were prepared by homogenizing in 50 mM Tris/HCl (pH 7.9), 150 mM 
KCl 20% glycerol, 0.1% NP-40, 5 mM -mercaptoethanol, 1× protease 
cocktail inhibitor, and clarification by centrifugation (15,000 rpm, 1 h) at 
4°C.  Immunoprecipitations  were  performed  using  Ab-p44  (1H5)  cross-
linked to protein A–Sepharose beads. After extensive washings (350 mM 
KCl), Western blots were performed using antibodies raised against p44, the 
His, or the Flag-tag.
NER assays. The single-lesion (Pt-GTG) plasmid was prepared as described 
previously (Araújo et al., 2000). Dual-incision assay was performed in 10 µl 
of a buffer containing 45 mM HepeS-KOH (pH 7.8), 5 mM MgCl2, 1 mM 
DTT, 0.3 mM EDTA, 10% glycerol, 2.5 µg BSA, 50 mM KCl, and 2 mM 
ATP. Each reaction contained XPG (5 ng), XPF/ERCC1 (15 ng), XPC/
hHR23B (10 ng), RPA (50 ng), XPA (25 ng), and 30 ng of rIIH complexes, 
and the reaction was conducted as previously described (Dubaele et al., 
2003).
Helicase assays. Helicase probe was prepared by mixing an oligonucleotide 
(5  ng)  corresponding  to  fragment  6219–6253  of  the  single-stranded 
M13mp18(+) DNA with single-stranded M13mp18() phage (1 µg) in the 
presence of NaCl (25 mM) and MgCl2 (2.5 mM). The mixture was heated 
for 2 min at 100°C and cooled slowly to room temperature to allow anneal-
ing of the DNA heteroduplex. Probe labeling was performed using Klenow 
fragment in the presence of dTTP (50 mM) and [-32P]dATP (70 µCi; 3000 
Ci/mmol; GE Healthcare). After phenol/chloroform extraction, the labeled 
probe was purified on a gel filtration column. Helicase assays were then per-
formed as previously described (Coin et al., 1998).
mutated protein might be more unstable than other XPD 
mutated forms, such as XPD/Q452X and XPD/I455del, 
allowing the XPD/R683W mutated protein to counteract the 
defects associated with XPD/199insPP.
Although differences in the genetic background may also 
account for the phenotypic variability (the identification of 
such modifier genes could also be of clinical significance), 
our results suggest that some presumed null XPD alleles might 
have an impact on the disease development in compound 
heterozygous humans. Strikingly, as summarized in Table I, 
the two brothers in family two had the same XPD mutations 
and similar severe XP symptoms of skin cancer and progres-
sive neurological degeneration leading to death in the fourth 
decade. In contrast, the affected brother and sister in family 
three had the same XPD mutations and similar mild symp-
toms of sun sensitivity without skin cancer or neurological 
abnormalities (Table I). Because all four XP patients had the 
XPD/R683W mutation, this suggests that the second XPD 
mutation in each family had a major role in determining the 
different clinical symptoms.
Collectively, these observations cast doubt the monoallelic 
assumption to explain the clinical heterogeneity in XPD com-
pound heterozygous, and instead support a biallelic hypothesis 
in which both alleles contribute to the phenotype (Andressoo 
et al., 2006). Previous studies hypothesized that XP is primarily 
a defect of NER and TTD a defect of transcription (van Steeg 
and Kraemer, 1999; Lehmann, 2001). However, the present 
study indicates that XPD mutations in XP patients affect both 
NER and transcription (Table II). Interestingly, it has been pre-
viously shown that the patient XP29BE had a poor response to 
isotretinoin, an oral retinoid used for chemoprevention of skin 
cancers (Kraemer et al., 1988). Our data suggest that this lower 
response might be caused by a weaker transactivation mediated 
by RAR. Moreover, depending on the nature of the combina-
tion of XPD mutations, this type of pharmacological treatment 
might have to be specifically adapted to efficiently prevent skin 
cancers in compound heterozygotes for XPD/R683W. Fur-
ther studies should thus be undertaken to reveal phenotypic ef-
fects attributable to combinations of differentially mutated XPD 
alleles and to examine the effect of concomitant mutations on 
the DNA repair and/or transcription processes.
MATERIALS AND METHODS
Experiments. The French Ministry of Higher Education and Research 
(Statement of Collections of Human Biological Samples for Scientific Pur-
poses n°DC-2008-785), the French Ethical Research Committee EST IV, 
and the National Cancer Institute Institutional Review Board approved the 
human experiments.
Host cell reactivation assay. The pCMV-luc vector was UV irradiated 
(254 nm, 1,000 J/m2) at a concentration of 1 mg/ml in 10 mM Tris-HCl 
(pH 8.0) and 1 mM EDTA. AS550 and AS552 cells were transfected with 
500 ng of pCMV (UV±) and 10 ng of pcDNA XPD WT in a 6-well plate 
at a confluence of 95% using Lipofectamine Plus (Invitrogen). To normalize 
transfection efficiencies, 100 ng of nonirradiated pCH110 vector expressing 
the -galactosidase (Invitrogen) was co-transfected. Cells were lysed after 24 h 
to measure the luciferase and the -galactosidase activities. The results are 
the mean of at least three measurements.3044 Biallelic effects in XP-D patients | Ueda et al.
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